^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    roniciclib (BAY1000394)

    i
    Associations
    News

    Trials

    Company:
    Bayer
    Drug class:
    CDK inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies (NCT01188252)
    Phase 1
    Bayer
    Completed
    Last update posted :
    01/09/2017
    Initiation :
    08/01/2010
    Primary completion :
    06/01/2016
    Completion :
    12/01/2016
    CASP3 • CDKN1A • ANXA5
    |
    MCL1 expression
    |
    roniciclib (BAY1000394)
    BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors (NCT02656849)
    Phase 2
    Dana-Farber Cancer Institute
    Withdrawn
    Last update posted :
    07/01/2016
    Initiation :
    02/01/2016
    Primary completion :
    10/01/2019
    Completion :
    05/01/2023
    MYC • CCNE1 • MCL1
    |
    MYC amplification • CCNE1 amplification • MCL1 amplification
    |
    roniciclib (BAY1000394)